Literature DB >> 9485004

Hypermethylation can selectively silence individual p16ink4A alleles in neoplasia.

S K Myöhänen1, S B Baylin, J G Herman.   

Abstract

Inactivation of p16ink4A and other tumor suppressor genes has been associated with promoter region hypermethylation in neoplasia. However, direct proof for aberrant DNA methylation as an independent event for loss of gene function has been difficult to obtain. We addressed this question in the colon carcinoma cell line HCT116, which contains one allele of p16ink4A with a coding region frameshift mutation and one wild-type allele. Neither allele contains a mutation in the proximal promoter region. The promoter of the wild-type allele, but not the mutant allele, is hypermethylated, and only the mutant allele is expressed. Transcription from the methylated/wild-type allele was restored after cell treatment with the demethylating agent 5-aza-2'-deoxycytidine. Thus, in neoplastic cells, stable allele-specific loss of transcription may arise from aberrant methylation of a nonmutated promoter region, identifying hypermethylation as a direct mechanism for tumor suppressor gene inactivation.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9485004

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  54 in total

1.  Selective association of the methyl-CpG binding protein MBD2 with the silent p14/p16 locus in human neoplasia.

Authors:  F Magdinier; A P Wolffe
Journal:  Proc Natl Acad Sci U S A       Date:  2001-04-17       Impact factor: 11.205

Review 2.  Epigenetic gene silencing in cancer.

Authors:  B Tycko
Journal:  J Clin Invest       Date:  2000-02       Impact factor: 14.808

3.  Cyclin-dependent kinases 4 and 6 control tumor progression and direct glucose oxidation in the pentose cycle.

Authors:  Miriam Zanuy; Antonio Ramos-Montoya; Oscar Villacañas; Nuria Canela; Anibal Miranda; Esther Aguilar; Neus Agell; Oriol Bachs; Jaime Rubio-Martinez; Maria Dolors Pujol; Wai-Nang P Lee; Silvia Marin; Marta Cascante
Journal:  Metabolomics       Date:  2011-07-08       Impact factor: 4.290

4.  Induction of the Cdk inhibitor p21 by LY83583 inhibits tumor cell proliferation in a p53-independent manner.

Authors:  Dimitri Lodygin; Antje Menssen; Heiko Hermeking
Journal:  J Clin Invest       Date:  2002-12       Impact factor: 14.808

Review 5.  DNA methylation changes in gastrointestinal disease.

Authors:  Minoru Toyota; Fumio Itoh; Takefumi Kikuchi; Ayumi Satoh; Toshiro Obata; Hiromu Suzuki; Suguru Ishii; Takao Endo; Takashi Tokino; Kohzoh Imai
Journal:  J Gastroenterol       Date:  2002-11       Impact factor: 7.527

6.  p16(Ink4a) inhibits histologic progression and angiogenic signaling in min colon tumors.

Authors:  Steven L Gibson; Amelie Boquoi; Tina Chen; Norman E Sharpless; Colleen Brensinger; Greg H Enders
Journal:  Cancer Biol Ther       Date:  2005-12-09       Impact factor: 4.742

7.  MLH1 promoter germline-methylation in selected probands of Chinese hereditary non-polyposis colorectal cancer families.

Authors:  Heng-Hua Zhou; Shi-Yan Yan; Xiao-Yan Zhou; Xiang Du; Tai-Ming Zhang; Xu Cai; Yong-Ming Lu; San-Jun Cai; Da-Ren Shi
Journal:  World J Gastroenterol       Date:  2008-12-28       Impact factor: 5.742

Review 8.  Epigenetic changes in the myelodysplastic syndrome.

Authors:  Jean-Pierre Issa
Journal:  Hematol Oncol Clin North Am       Date:  2010-04       Impact factor: 3.722

9.  Predicting aberrant CpG island methylation.

Authors:  F A Feltus; E K Lee; J F Costello; C Plass; P M Vertino
Journal:  Proc Natl Acad Sci U S A       Date:  2003-09-30       Impact factor: 11.205

10.  Aberrant promoter methylation and reduced expression of p16 gene in esophageal squamous cell carcinoma from Kashmir valley: a high-risk area.

Authors:  Irfana Salam; Showket Hussain; Mohammad Muzaffar Mir; Nazir Ahmad Dar; Safiya Abdullah; Mushtaq Ahmad Siddiqi; Riyaz Ahmad Lone; Showkat Ahmad Zargar; Shashi Sharma; Suresh Hedau; Seemi Farhat Basir; Alok Chandra Bharti; Bhudev C Das
Journal:  Mol Cell Biochem       Date:  2009-06-10       Impact factor: 3.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.